KBP Biosciences is a clinical-stage biotech founded in Jinan, China with a medicinal chemistry platform and preclinical development team focused on advancing novel small-molecule NCEs. Its lead program, KBP-5074, is a mineralocorticoid receptor antagonist for cardiovascular disease that is entering Phase 2b. The company also has KBP-7072, a 3rd‑generation aminomethylcycline that completed Phase 1 and holds FDA QIDP and Fast Track designations, and KBP-7026, a CRTH2 antagonist with an approved IND ready for Phase 1. KBP plans to open global corporate headquarters in the Greater Philadelphia Area and expand its US clinical, commercial and corporate capabilities. The company announced the appointment of Brian P. McVeigh as Chief Executive Officer to lead its global development and business‑development efforts. KBP says the Series A proceeds will be used to advance clinical development, expand operations and support other programs in the pipeline.

Total raised

$76M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2018